November 7, 2018Open Access
View Full PaperElotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Key Points
Key points are not available for this paper at this time.
Abstract
Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3 ClinicalTrials.gov number, NCT02654132 .).